Sunovion announces U.S. FDA approval of Kynmobi (apomorphine hydrochloride) sublingual film for the treatment of Parkinson’s disease OFF episodes

Sunovion Pharmaceuticals

21 May 2020 - First and only sublingual therapy approved for the on-demand treatment of Parkinson’s disease OFF episodes.

Sunovion Pharmaceuticals announced today that the U.S. FDA has approved Kynmobi (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease.

Sunovion expects Kynmobi to be available in U.S. pharmacies in September 2020.

Read Sunovion Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US